What Caused RYTHM (RYM) Stock to Surge More Than 23% Overnight?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: Benzinga
Stock Performance: RYTHM Inc. shares rose 23.3% in after-hours trading to $30, despite a 21.52% drop during regular trading, closing at $24.33. The stock has seen a 46.54% decline over the past month.
Q3 Financial Results: The company reported a 98% increase in third-quarter revenue from continuing operations, reaching $4 million, while ending the quarter with $35.6 million in cash despite an $8.9 million operating loss.
Retail Expansion: RYTHM's THC beverage, Señorita THC Margaritas, launched in over 1,000 Circle K stores and select Target locations, marking significant retail expansion for hemp-derived THC products.
Strategic Developments: The company acquired intellectual property for several iconic brands and rebranded from Agrify Corporation to RYTHM Inc., positioning itself to benefit from the growing acceptance of THC beverages among consumers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYM
About RYM
RYTHM, Inc., formerly Agrify Corporation, is a provider of branded innovative solutions for the cannabis and hemp industries. The Company’s portfolio of brands includes RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, & Shine, Doctor Solomon’s and Good Green in thousands of physical locations and online channels. The Company’s portfolio of consumer-packaged goods brands includes Senorita brand which offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror well-known cocktails like a margarita in four flavors, including classic Lime JalapeNo Margarita, Mango Margarita, Paloma and Ranch Water. Senorita offers a low-sugar, low-calorie alternative to alcoholic beverages and is available at retailers, including Total Wine, ABC Fine Wine & Spirits, and Binny’s in 11 U.S. states and Canada. Its comprehensive extraction product line includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Green Thumb Industries Shows Profit Growth Potential Amid Cannabis Market Trends
- Profitability Advantage: Green Thumb Industries has maintained GAAP profitability since 2020, showcasing its financial strength in the competitive U.S. cannabis market, making it a favored choice for bullish investors.
- Licensing Agreement Renegotiation: The company renegotiated its licensing deal with 50%-owned Rythm to a flat fee structure, which is expected to significantly enhance operating leverage and drive future profitability growth.
- Stock Buyback Program: Green Thumb recently increased its stock repurchase program ceiling by $100 million, equivalent to about 6% of its total share count, a move that not only enhances shareholder value but could also elevate its stock price in the market.
- Market Entry in Texas: As one of the multi-state operators granted a conditional license, Green Thumb will operate in Texas' upcoming legalized medical cannabis market, further expanding its market share and enhancing future growth potential.
See More
Green Thumb Industries Shows Strong Profitability Potential
- Sustained Profitability: Green Thumb Industries has reported GAAP profitability since 2020, demonstrating consistent earnings that position it favorably against Canadian competitors struggling for profitability.
- Optimized Licensing Agreement: The company renegotiated its licensing deal with 50%-owned Rythm to a flat fee structure, enhancing operational leverage and potentially driving significant earnings growth in the future.
- Stock Buyback Program: Green Thumb recently increased its stock repurchase program ceiling by $100 million, representing about 6% of its total share count, which not only boosts shareholder returns but may also elevate the stock price.
- Market Expansion Opportunities: The company has secured a conditional license to operate in Texas' upcoming legalized medical cannabis market, further expanding its market share and expected to provide strong momentum for future growth.
See More
Ryman Healthcare Reports Doubling of EBITDA and Positive Cash Flow
- Strong Financial Performance: Ryman Healthcare achieved positive free cash flow of $188 million for the first time, with operating EBITDA doubling, indicating significant improvements in financial management and boosting investor confidence.
- Significant Cost Savings: The company realized $57 million in annualized cost savings since FY24, exceeding expectations, which enhances profitability and provides funding for future investments.
- High Occupancy Rates: New care centers reached 90% occupancy, surpassing expectations, indicating strong market demand that will help increase overall revenue and market share.
- Optimized Debt Management: Net debt was reduced by $94 million to $1.57 billion, with the average cost of debt decreasing to 5.9%, which will lower financial expenses and enhance the company's financial flexibility.
See More
Green Thumb's DEA Registration: A Historic Move
- Industry Transformation Opportunity: The DEA's rescheduling of marijuana to Schedule III on April 23, 2026, signifies a shift in perception, categorizing it as having 'moderate to low potential for physical and psychological dependence,' laying the groundwork for the normalization of the medical cannabis industry.
- Strategic Move by Green Thumb: On May 4, 2026, Green Thumb Industries submitted applications to register its state-licensed medical cannabis operations, with CEO Ben Kovler stating that this step will shape the future of medical cannabis in America.
- Investor Confidence Boost: Kovler noted during the quarterly conference call that the DEA registration is expected to attract a significant influx of institutional investors, which could drive Green Thumb's stock price higher and reinforce its position as a leading multistate cannabis operator.
- Research Collaboration Potential: The rescheduling of cannabis may lead to research partnerships with biotech and pharmaceutical companies, enhancing industry development and strengthening Green Thumb's competitive edge in the market.
See More
RYTHM Partners with Navy Pier as Official THC Beverage Brand
- Partnership Announcement: RYTHM, Inc. has established a multi-year partnership with Navy Pier, becoming the official THC beverage partner at a venue that attracts over 8 million visitors annually, significantly enhancing brand visibility and market penetration.
- Product Launch: Starting May 22, RYTHM will introduce its full lineup of THC beverages, including 5mg hemp-derived THC cans, at the Navy Pier Beer Garden, catering to consumer demand for innovative drinks and driving potential sales growth.
- Market Expansion: This partnership marks RYTHM's ongoing expansion into major U.S. entertainment venues, following its historic sponsorship at Chicago's United Center, further solidifying its leadership position in the THC beverage market.
- Cultural Impact: Navy Pier's Chief of Advancement noted that RYTHM's presence will inject new energy into summer programming, supporting public initiatives and enhancing visitor experiences, showcasing the brand's deep integration with this cultural landmark.
See More
Green Thumb Industries Faces Challenges but Analysts Remain Bullish
- Stock Price Decline: As of April 21, Green Thumb Industries' shares have fallen 10% year-to-date, primarily due to slow progress in reforming federal marijuana restrictions in the U.S., which has dampened investor confidence and affected market performance.
- Analyst Optimism: Despite challenges, analysts maintain an average price target of $18.50 per share for Green Thumb, over 100% above the current price, reflecting market expectations for future marijuana law reforms and recognition of the company's potential.
- Profitability Improvement: Green Thumb has been profitable since 2019, operating 113 retail stores and 20 manufacturing facilities; although revenue grew only 3.3% last year, the newly introduced flat-fee licensing model is expected to significantly enhance future profitability.
- Change in Licensing Model: The company announced it will pay a flat $70 million in licensing fees annually, increasing only with the Consumer Price Index, which is expected to help boost incremental earnings and drive further profit growth.
See More
Green Thumb Industries Shows Profit Growth Potential Amid Cannabis Market Trends
- Profitability Advantage: Green Thumb Industries has maintained GAAP profitability since 2020, showcasing its financial strength in the competitive U.S. cannabis market, making it a favored choice for bullish investors.
- Licensing Agreement Renegotiation: The company renegotiated its licensing deal with 50%-owned Rythm to a flat fee structure, which is expected to significantly enhance operating leverage and drive future profitability growth.
- Stock Buyback Program: Green Thumb recently increased its stock repurchase program ceiling by $100 million, equivalent to about 6% of its total share count, a move that not only enhances shareholder value but could also elevate its stock price in the market.
- Market Entry in Texas: As one of the multi-state operators granted a conditional license, Green Thumb will operate in Texas' upcoming legalized medical cannabis market, further expanding its market share and enhancing future growth potential.
See More
Green Thumb Industries Shows Strong Profitability Potential
- Sustained Profitability: Green Thumb Industries has reported GAAP profitability since 2020, demonstrating consistent earnings that position it favorably against Canadian competitors struggling for profitability.
- Optimized Licensing Agreement: The company renegotiated its licensing deal with 50%-owned Rythm to a flat fee structure, enhancing operational leverage and potentially driving significant earnings growth in the future.
- Stock Buyback Program: Green Thumb recently increased its stock repurchase program ceiling by $100 million, representing about 6% of its total share count, which not only boosts shareholder returns but may also elevate the stock price.
- Market Expansion Opportunities: The company has secured a conditional license to operate in Texas' upcoming legalized medical cannabis market, further expanding its market share and expected to provide strong momentum for future growth.
See More
Ryman Healthcare Reports Doubling of EBITDA and Positive Cash Flow
- Strong Financial Performance: Ryman Healthcare achieved positive free cash flow of $188 million for the first time, with operating EBITDA doubling, indicating significant improvements in financial management and boosting investor confidence.
- Significant Cost Savings: The company realized $57 million in annualized cost savings since FY24, exceeding expectations, which enhances profitability and provides funding for future investments.
- High Occupancy Rates: New care centers reached 90% occupancy, surpassing expectations, indicating strong market demand that will help increase overall revenue and market share.
- Optimized Debt Management: Net debt was reduced by $94 million to $1.57 billion, with the average cost of debt decreasing to 5.9%, which will lower financial expenses and enhance the company's financial flexibility.
See More
Green Thumb's DEA Registration: A Historic Move
- Industry Transformation Opportunity: The DEA's rescheduling of marijuana to Schedule III on April 23, 2026, signifies a shift in perception, categorizing it as having 'moderate to low potential for physical and psychological dependence,' laying the groundwork for the normalization of the medical cannabis industry.
- Strategic Move by Green Thumb: On May 4, 2026, Green Thumb Industries submitted applications to register its state-licensed medical cannabis operations, with CEO Ben Kovler stating that this step will shape the future of medical cannabis in America.
- Investor Confidence Boost: Kovler noted during the quarterly conference call that the DEA registration is expected to attract a significant influx of institutional investors, which could drive Green Thumb's stock price higher and reinforce its position as a leading multistate cannabis operator.
- Research Collaboration Potential: The rescheduling of cannabis may lead to research partnerships with biotech and pharmaceutical companies, enhancing industry development and strengthening Green Thumb's competitive edge in the market.
See More
RYTHM Partners with Navy Pier as Official THC Beverage Brand
- Partnership Announcement: RYTHM, Inc. has established a multi-year partnership with Navy Pier, becoming the official THC beverage partner at a venue that attracts over 8 million visitors annually, significantly enhancing brand visibility and market penetration.
- Product Launch: Starting May 22, RYTHM will introduce its full lineup of THC beverages, including 5mg hemp-derived THC cans, at the Navy Pier Beer Garden, catering to consumer demand for innovative drinks and driving potential sales growth.
- Market Expansion: This partnership marks RYTHM's ongoing expansion into major U.S. entertainment venues, following its historic sponsorship at Chicago's United Center, further solidifying its leadership position in the THC beverage market.
- Cultural Impact: Navy Pier's Chief of Advancement noted that RYTHM's presence will inject new energy into summer programming, supporting public initiatives and enhancing visitor experiences, showcasing the brand's deep integration with this cultural landmark.
See More
Green Thumb Industries Faces Challenges but Analysts Remain Bullish
- Stock Price Decline: As of April 21, Green Thumb Industries' shares have fallen 10% year-to-date, primarily due to slow progress in reforming federal marijuana restrictions in the U.S., which has dampened investor confidence and affected market performance.
- Analyst Optimism: Despite challenges, analysts maintain an average price target of $18.50 per share for Green Thumb, over 100% above the current price, reflecting market expectations for future marijuana law reforms and recognition of the company's potential.
- Profitability Improvement: Green Thumb has been profitable since 2019, operating 113 retail stores and 20 manufacturing facilities; although revenue grew only 3.3% last year, the newly introduced flat-fee licensing model is expected to significantly enhance future profitability.
- Change in Licensing Model: The company announced it will pay a flat $70 million in licensing fees annually, increasing only with the Consumer Price Index, which is expected to help boost incremental earnings and drive further profit growth.
See More
